Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

ATM gene and lymphoid malignancies

Leukemia volume 18, pages 238–242 (2004)Cite this article

Abstract

Inherited biallelic mutations of the ATM (ataxia-telangiectasia mutated) gene cause ataxia-telangiectasia, a rare autosomal recessive disorder associated with a high incidence of childhood leukaemias and lymphomas, suggesting that ATM gene alterations may be involved in lymphomagenesis. Loss of heterozygosity at 11q22–23 (location of the ATM gene) is a frequent event in sporadic lymphoid tumours, and several studies have reported a high prevalence of ATM gene alterations in diverse sporadic lymphoproliferative disorders, adding evidence to the postulated contribution of ATM in the pathogenesis of these tumours. This mini-review will summarize the recently published data concerning the ATM gene in sporadic lymphoid malignancies and will discuss the apparent paradox between the predominance of nonsense mutations observed in patient with ataxia-telangiectasia and the high proportion of missense alterations found in sporadic lymphoid tumours.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Peterson RD, Funkhouser JD, Tuck-Muller CM, Gatti RA . Cancer susceptibility in ataxia-telangiectasia. Leukemia 1992; 6 (Suppl. 1): 8–13.

    PubMed  Google Scholar 

  2. Taylor AM, Metcalfe JA, Thick J, Mak YF . Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87: 423–438.

    CAS  PubMed  Google Scholar 

  3. Khanna KK, Lavin MF, Jackson SP, Mulhern TD . ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001; 8: 1052–1065.

    Article  CAS  PubMed  Google Scholar 

  4. Shiloh Y . ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155–168.

    Article  CAS  PubMed  Google Scholar 

  5. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998; 62: 334–345.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Telatar M, Wang S, Castellvi-Bel S, Tai LQ, Sheikhavandi S, Regueiro JR et al. A model for ATM heterozygote identification in a large population: four founder-effect ATM mutations identify most of Costa Rican patients with ataxia telangiectasia. Mol Genet Metab 1998; 64: 36–43.

    Article  CAS  PubMed  Google Scholar 

  7. Li A, Swift M . Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. Am J Med Genet 2000; 92: 70–77.

    Article  Google Scholar 

  8. Buzin CH, Gatti RA, Nguyen VQ, Wen CY, Mitui M, Sanal O et al. Comprehensive scanning of the ATM gene with DOVAM-S. Hum Mutat 2003; 21: 123–131.

    Article  CAS  PubMed  Google Scholar 

  9. Elson A, Wang Y, Daugherty C, Morton CC, Zhou F, Campos-Torres J et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci USA 1996; 93: 13084–13089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Athma P, Rappaport R, Swift M . Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996; 92: 130–134.

    Article  CAS  PubMed  Google Scholar 

  11. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997; 15: 307–310.

    Article  CAS  PubMed  Google Scholar 

  12. Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 2001; 92: 479–487.

    Article  CAS  PubMed  Google Scholar 

  13. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001; 61: 7608–7615.

    CAS  PubMed  Google Scholar 

  14. Maillet P, Bonnefoi H, Vaudan-Vutskits G, Pajk B, Cufer T, Foulkes WD et al. Constitutional alterations of the ATM gene in early onset sporadic breast cancer. J Med Genet 2002; 39: 751–753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Maillet P, Chappuis PO, Vaudan G, Dobbie Z, Muller H, Hutter P et al. A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer 2000; 88: 928–931.

    Article  CAS  PubMed  Google Scholar 

  16. Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC et al. Clustering of missense mutations in ataxia telangiectasia gene in sporadic T-cell leukemia. Nat Genet 1997; 17: 96–99.

    Article  CAS  PubMed  Google Scholar 

  17. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 10: 1155–1159.

    Article  Google Scholar 

  18. Stoppa-Lyonnet D, Lauge A, Sigaux F, Stern MH . No germline ATM mutation in a series of 16 T-cell prolymphocytic leukemias. Blood 2000; 96: 374–376.

    CAS  PubMed  Google Scholar 

  19. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E et al. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 2000; 88: 1057–1062.

    Article  CAS  PubMed  Google Scholar 

  20. Gronbaek K, Worm J, Ralfkiaer E, Ahrenkiel V, Hokland P, Guldberg P . ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 2002; 100: 1430–1437.

    Article  CAS  PubMed  Google Scholar 

  21. Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Milani R, Bardi A et al. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features. J Clin Oncol 2000; 18: 2607–2614.

    Article  CAS  PubMed  Google Scholar 

  22. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999; 59: 24–27.

    CAS  PubMed  Google Scholar 

  23. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26–29.

    Article  CAS  PubMed  Google Scholar 

  24. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M et al. Deficiency of ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukaemia. Cancer Res 1998; 58: 4552–4557.

    CAS  PubMed  Google Scholar 

  25. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99: 300–309.

    Article  CAS  PubMed  Google Scholar 

  26. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P . Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748–753.

    CAS  PubMed  Google Scholar 

  27. Yuille MR, Condie A, Hudson CD, Bradshaw PS, Stone EM, Matutes E et al. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 2002; 100: 603–609.

    Article  CAS  PubMed  Google Scholar 

  28. Stilgenbauer S, Winkler D, Ott G, Schaffner C, Leupolt E, Bentz M et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 1999; 94: 3262–3264.

    CAS  PubMed  Google Scholar 

  29. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P . Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97: 2773–2778.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002; 99: 238–244.

    Article  CAS  PubMed  Google Scholar 

  31. Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 2003; 100: 5372–5377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822.

    Article  CAS  PubMed  Google Scholar 

  33. Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K et al. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res 2002; 8: 3813–3819.

    CAS  PubMed  Google Scholar 

  34. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999; 17: 1259–1266.

    Article  CAS  PubMed  Google Scholar 

  35. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol 2000; 76: 693–698.

    Article  CAS  PubMed  Google Scholar 

  36. Luo L, Lu FM, Hart S, Foroni L, Rabbani H, Hammarstrom L et al. Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. Cancer Res 1998; 58: 2293–2297.

    CAS  PubMed  Google Scholar 

  37. Takeuchi S, Koike M, Park S, Seriu T, Bartram CR, Taub HE et al. The ATM gene and susceptibility to childhood T-cell acute lymphoblastic leukemia. Br J Haematol 1998; 103: 536–538.

    Article  CAS  PubMed  Google Scholar 

  38. Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 2003; 101: 3622–3627.

    Article  CAS  PubMed  Google Scholar 

  39. Gumy Pause F, Wacker P, Maillet P, Betts D, Sappino AP . ATM alterations in childhood acute lymphoblastic leukemias. Hum Mutat 2003; 21: 554.

    Article  PubMed  Google Scholar 

  40. Gatti RA, Tward A, Concannon P . Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999; 68: 419–423.

    Article  CAS  PubMed  Google Scholar 

  41. Meyn MS . Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 1999; 55: 289–304.

    Article  CAS  PubMed  Google Scholar 

  42. Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF . Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 2002; 99: 925–930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet 2002; 32: 185–190.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Hematology/Oncology Unit, University Hospital of Geneva, Switzerland

    F Gumy-Pause & P Wacker

  2. Division of Oncology, University Hospital of Geneva, Switzerland

    F Gumy-Pause & A-P Sappino

Authors
  1. F Gumy-Pause
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Wacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A-P Sappino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Gumy-Pause.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gumy-Pause, F., Wacker, P. & Sappino, AP. ATM gene and lymphoid malignancies. Leukemia 18, 238–242 (2004). https://doi.org/10.1038/sj.leu.2403221

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403221

Keywords

This article is cited by

Search

Advanced search

Quick links